Science News, Information and Educational Resources


Science Feed Image

    		•    
    The majority of men will develop an enlarged prostate sometime in their lifetime. The symptoms include: difficulting in starting urination, weak flow of urination, need to urinate frequently. Men that suffer from these symptoms should seek medical advice to ensure that it only an enlarged prostate that is causing the problem, and not prostate cancer. Prostate cancer is the second largest cause of cancer deaths among men, second only to lung cancer. One of the problems with prostate cancer, is that the symptoms typically do not show up in the early stages of the disease, and when they do manifest themselves, it is often in the late stages of the disease and makes it difficult to treat. The main symptoms of prostate cancer include the same symptoms as an enlarged prostate, but the advanced stages also include: Pain in back, hips and thighs; unexplained weight loss; feeling of tiredness. Most prostate cancers are treated by surgery or radiation therapy. At the present time, there is not a good chemotherapy option for the early stages of prostate cancer. Surgery is the most common method of treating the early stages of prostate cancer. But there are risks with any type of surgery, and many men are turning to radiation treatment. Radiation therapy works by killing the cancer cells and not killing the adjacent healthy cells. The two most common methods for radiation therapy include seed therapy and external beam radiation therapy. Seed therapy involves implanting a small amount (a seed) of radioactive material in the prostate. The radioactive material will last about two years, in which time the cancerous cells have been killed. External Beam radiation therapy is a painless, out patient procedure where a beam is aimed at the affected areas. If the area has spread, the radiation can be aimed at it as well. The treatment takes place five days a week over a seven week period. The side effects of prostrate cancer radiation treatment include incontinence, impotence, and fatigue. Not all patients suffer from these side effects. Treatment for the early stages of prostate cancer is usually successful. However, if the prostate cancer is not identified in its early stages, then the success rate drops dramatically. This is why all men over the age of 50 should have a yearly check up to identify prostrate cancer early. lungcancertreatment.blognub.com


      ...Read On

    Targeted biopsy, a major advance in prostate cancer diagnostics, was detailed by a UCLA team in the current issue of Urologic Oncology. The new technology fuses MRI with real-time 3D ultrasound, providing an exacting method to obtain biopsy specimens from suspicious areas in the prostate. www.news-medical.net


      ...Read On

    The interview with Dr Charles Sawyers from Memorial-Sloan Kettering recently, talking about his role in Medivation’s MDV3100, turned out to be rather good timing. On Friday, Medivation announced their 1Q earnings and clinical progress. The big news is that aside from the ongoing phase III trials in castrate-resistant prostrate cancer (CRPC) before (PREVAIL) and after failure of docetaxel (AFFIRM), the company are seeking to explore the use of MDV3100 earlier in the disease. This makes a lot of sense, both clinically and strategically. A phase II trial is already open in the pre-chemotherapy setting, comparing MDV3100 to bicalutamide (TERRAIN). Highlights The first phase II trial evaluates the combination of MDV3100 with bicalutamide in the treatment of advanced prostate cancer patients who have progressed while on LHRH analogue therapy or following surgical castration. TERRAIN is expected to enroll approximately 370 patients in North America and Europe. The primary endpoint of the trial is progression-free survival. This trial is ongoing and patients are enrolling. A second phase II trial has now opened and is the first trial to examine the effects of MDV3100 without medical or surgical castration. Patients will be given MD3100 monotherapy and “enrolled patients would not have had any previous hormonal therapies for the treatment of prostate cancer.” In other words, both hormone and chemotherapy naive, so very early in the prostate cancer treatment cycle where LHRH analogues are traditionally given. On Friday, Medivation announced that the first patient has now begun treatment with MDV3100 in this setting. Approx. 60 patients will be enrolled in Europe, with PSA as the primary endpoint and will take MDV3100 orally for 24 weeks (160 mg dose). The main phase III registration trial, AFFIRM, is a randomized, double-blind, placebo-controlled study in 1,199 patients with advanced prostate cancer who were previously treated with docetaxel-based chemotherapy. MDV3100 was compared to MDV3100 versus placebo. The primary endpoint is overall survival. The study completed enrollment last November, so Medivation plan an interim analysis by the end of the year. Interestingly, MDV3100 is now being positioned as “a triple-acting oral androgen receptor antagonist.” As Dr Sawyers noted in the interview, MDV3100 and abiraterone (Zytiga) have very different mechanisms of action in throttling either the androgren receptor signaling directly, or by inhibiting testosterone production that drives tumour growth through CYP17 inhibition. What does all this data mean? On Friday this week, I’ll be heading off to the annual meeting of the American Urology Association (AUA) and will be live tweeting, blogging and vlogging the event to see what urologists and oncologists think of these new developments. Essentially, abiraterone’s recent FDA approval means that they will compete head to head with Sanofi’s cabazitaxel (Jevtana) in the post Taxotere setting, and Medivation look to be about 18 months behind with MDV3100, although the latter are aggressively expanding their trial program earlier in the disease, where I think it will have a more lasting impact. The proof of concept for androgen receptor antagonists has already been proven with bicalutamide, so the question there is whether MDV3100 will be a more complete and effective inhibitor. In the long run, a phase II trial combining abiraterone and MDV3100 to take advantage of their different mechanisms of action in early prostate cancer makes a lot of sense. The last few weeks have provided some amusement with naysayers insisting that the PDUFA date for abiraterone wasn’t until October instead of realising it was getting Priority approval early (oops) and that the MDV3100 phase III trial couldn’t possibly be mature for an interim analysis by year end (another oops). I’m glad I called both of those correctly This leads me to ponder the next controversy – will urologists use these new hormonal agents in the pre-chemo setting once approved in the post chemo setting? My hunch is yes based on the overwhelming feedback I heard this year at both ASCO GU and the European Association of Urology meeting in Vienna. I say this with hindsight, knowing that many people insisted when imatinib (Gleevec) was approved for CML in refractory and advanced disease, that it wouldn’t be used front-line without FDA approval. When we looked at the data at the end of 7 seven months from approval, guess what? There was a fair bit of front-line use even without compendia listing, so it can happen when there is pent up demand and high desire to use a product. My sense is that will happen here too, especially as bicalutamide and ketoconazole are already well established in the prostate cancer treatment paradigm as patients cycle through multiple therapies, but we will see. Urologists, we all know, much prefer pills over the complexity of infusional therapies. What’s next? In the meantime, with another round of urology and cancer conferences coming up, we can expect to see the final OS survival data from the FDA submission for abiraterone presented at AUA by Fred Saad and an update on the much awaited circulating tumour cells (CTC’s) data from Prof De Bono at ASCO. All in all, it’s going to be a very interesting two months!    Update on new data in prostate cancer by MaverickNY ©Pharma Strategy Blog Update on new data in prostate cancer originally appeared on Pharma Strategy Blog on May 9, 2011. feedproxy.google.com


      ...Read On

    What is Benign prostatic hyperplasia in Prostate Cancer Prostate cancer is a cancerous growth which forms in the reproductive gland of the male called the prostate. It is possible for the cancer cells to spread to the lymph nodes and into bones. This type of cancer can cause pain whilst urinating and may cause erectile dysfunction. Prostate cancer is usually slow growing, but there are the cases of rapidly growing prostate cancer cells which develop faster and are cause for concern. Many cases of prostrate cancer go unnoticed as in most cases the cancer is symptom free. Prostrate cancer is usually detected by a biopsy with a cat scan to see if the cancer has spread. benign prostatic hyperplasia is the medical term used for an enlarged prostrate gland by way of individual discreet nodules of growths forming in the prostate gland causing an inability to urinate. Prostate cancer surgery is used to cut out the cancerous growth and is classed as a major surgery. Radical prostatectomy as the surgery is called, may not be carried out if the patient has other diseases which may affect the outcome. An MRI scan will evaluate each patient prior to any prostate cancer surgery being recommended. Laparoscopic prostatectomy is the surgery for prostate cancer which relies on minimal incisions to the body. This technique uses technologically advanced methods such as miniaturization and fibre optics to destroy the cancerous growth. All surgery carries a certain element of risk, and a consultant will evaluate and inform any patient before, during, and after surgery. prostate cancer treatment,prostate treatment,prostate surgery Article from articlesbase.com Find More Prostate Cancer Articles Cancer HealthIs prostate cancer so pessimistic? Offers treatment for prostate cancer HopeProstate Cancer TreatmentsHEEDING PROSTATE CANCER WARNING SIGNSThe Man Killer – Prostate CancerMen Need To Slim Down And Pump Up To Avoid Prostate CancerProstate Cancer Treatment – How to Detect Early Signs www.newhealthidea.com


      ...Read On

    NeoTract, Inc. a medical device company focused on developing urology devices, today announced that the first U.S. patients have been enrolled in a multinational trial of its UroLift® System at Western Urological Clinic in Salt Lake City, Utah. www.news-medical.net


      ...Read On


    		   
    You can link to this article on your web site using following code:

    Website Code:

    Forum Code:  




     
    		 
    Comments

    We're looking for comments that are interesting, substantial or highly amusing. If your comments are excessively self-promotional (use your real name, no keywords please), obnoxious, or even worse, boring, you will be banned from commenting. Your comment must be related to the post. Please do not comment on how great or wonderful the post is. All comments are moderated and, if approved, will display in less than 24 hours.


    blog comments powered by Disqus